RB1 mutations are seen in 40-60% of sporadic osteosarcoma. Here, the authors demonstrate a selective sensitivity to PARP inhibitors in RB1-mutated osteosarcoma-derived cell lines that is not associated with canonical signatures indicative of a homologous recombination defect.
- Georgia Zoumpoulidou
- Carlos Alvarez-Mendoza
- Sibylle Mittnacht
